Alpha Tau Medical Q2 2023 Earnings Report $3.80 +0.15 (+4.11%) As of 04:00 PM Eastern Earnings HistoryForecast Alpha Tau Medical EPS ResultsActual EPS-$0.13Consensus EPS -$0.13Beat/MissMet ExpectationsOne Year Ago EPSN/AAlpha Tau Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlpha Tau Medical Announcement DetailsQuarterQ2 2023Date8/28/2023TimeN/AConference Call ResourcesPress ReleaseDRTS Earnings HistoryPowered by Alpha Tau Medical Earnings HeadlinesAlpha Tau DaRT Shows Promising Interim Data In Cancer Trials, Shares RiseJanuary 29 at 7:32 PM | nasdaq.comAlpha Tau announces interim data from pembrolizumab combination trialJanuary 28 at 6:59 PM | markets.businessinsider.comIs this the pin that pops the bubble? CEO Jensen Huang does not want you knowing this dirty little secret about Nvidia… In fact, any day now we’re expecting a cease and desist from Nvidia’s lawyers. Go here now before it’s too late to find out why Nvidia shares are slumping so hard.January 30, 2025 | Porter & Company (Ad)Alpha Tau receives IDE from FDA for study evaluating Alpha DaRT, chemo comboJanuary 27 at 2:12 PM | markets.businessinsider.comAlpha Tau shares interim data across multiple clinical trials at R&D Update DayJanuary 27 at 2:12 PM | markets.businessinsider.comDRTS Stock Soars to 52-Week High, Reaching $4.12 Amid Healthcare SurgeJanuary 27 at 2:12 PM | msn.comSee More Alpha Tau Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email. Email Address About Alpha Tau MedicalAlpha Tau Medical (NASDAQ:DRTS), a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.View Alpha Tau Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings AbbVie (1/31/2025)AON (1/31/2025)Colgate-Palmolive (1/31/2025)Chevron (1/31/2025)Eaton (1/31/2025)W.W. Grainger (1/31/2025)Novartis (1/31/2025)Snowflake (1/31/2025)Itaú Unibanco (2/2/2025)NXP Semiconductors (2/3/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
